Your browser doesn't support javascript.
loading
Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma.
Ng, Yuen Lam Dora; Ramberger, Evelyn; Bohl, Stephan R; Dolnik, Anna; Steinebach, Christian; Conrad, Theresia; Müller, Sina; Popp, Oliver; Kull, Miriam; Haji, Mohamed; Gütschow, Michael; Döhner, Hartmut; Walther, Wolfgang; Keller, Ulrich; Bullinger, Lars; Mertins, Philipp; Krönke, Jan.
Afiliação
  • Ng YLD; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Ramberger E; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Bohl SR; Proteomics Platform, Max Delbrück Center for Molecular Medicine, Berlin, Germany.
  • Dolnik A; German Cancer Consortium (DKTK) partner site Berlin and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Steinebach C; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
  • Conrad T; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Müller S; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Popp O; Department of Pharmaceutical & Medicinal Chemistry, Pharmaceutical Institute, University of Bonn, Bonn, Germany.
  • Kull M; Experimentelle Pharmakologie & Onkologie (EPO) Berlin-Buch GmbH, Berlin, Germany.
  • Haji M; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Gütschow M; Proteomics Platform, Max Delbrück Center for Molecular Medicine, Berlin, Germany.
  • Döhner H; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
  • Walther W; Proteomics Platform, Max Delbrück Center for Molecular Medicine, Berlin, Germany.
  • Keller U; Department of Pharmaceutical & Medicinal Chemistry, Pharmaceutical Institute, University of Bonn, Bonn, Germany.
  • Bullinger L; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
  • Mertins P; Experimental and Clinical Research Center, Charité Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.
  • Krönke J; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Nat Commun ; 13(1): 1009, 2022 02 23.
Article em En | MEDLINE | ID: mdl-35197447
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quinase 6 Dependente de Ciclina / Lenalidomida / Mieloma Múltiplo Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Nat Commun Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quinase 6 Dependente de Ciclina / Lenalidomida / Mieloma Múltiplo Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Nat Commun Ano de publicação: 2022 Tipo de documento: Article